SCIEX, a global leader in life science analytical technologies, system at Echo® MS+.The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results, through an expanded panel of robust high-throughput screening workflows.
The system addresses key challenges in high-throughput screening applications for drug discovery without the need for extensive method development. This is achieved through the introduction of new, flexible workflows for small and large molecules that leverage the capabilities of high-resolution mass spectrometry for improved selectivity and sensitivity compared to other analytical tools.
Through a combination of high speed of analysis, high data quality and minimal sample and reagent consumption, the system has the potential to reduce the time, cost and risk in making critical decisions during the early phases of the drug development pipeline. With this expanded capability, researchers in drug discovery will have the ability to make faster and more confident decisions in hit identification and iterative lead optimization. This will help speed up the process of drug discovery and reduce the potential for false positive or false negative results.
“Building on the speed and fidelity of results that this technology can deliver by integrating it with high resolution mass spectrometry is going to enable us to develop new and novel workflows across a range of molecule types for high-throughput screening applications,” said Jose Castro-Perez, vice president of product management at SCIEX. “Moving forward we intend to develop further new and novel workflows for the Echo® MS+ system in collaboration with customers at our global Echo® MS Center of Excellence. The goal is to address key unmet analytical needs with this disruptive technology.”
For more information, please visit www.sciex.com.
